Andrew J. Cowan, MD

Interim Clinical Director, Myeloma Service; Physician
Seattle Cancer Care Alliance
Assistant Professor, Division of Medical Oncology
University of Washington School of Medicine
Research Associate, Clinical Research Division
Fred Hutchinson Cancer Research Center
Specialty:
Medical Oncology
“The foundation of a cancer success story is teamwork.”
— Dr. Cowan
Why did you become a physician?

When my mother was in her twenties, she was diagnosed with advanced-stage Hodgkin lymphoma. It was a harrowing time for her, but she was cured through a combination of radiation and chemotherapy, and her success story inspired me to pursue medicine, eventually specializing in oncology. One of the great things about following this path is the mentors you meet along the way. During my fellowship at the Boston University Amyloidosis Center, I worked with some excellent oncologists whose clinical expertise, kindness toward their patients and passion for research continue to inspire me to this day.

Andrew_Cowan_Secondary.jpg
What’s it like to work with you?

The physician-patient relationship is all about teamwork. Together, we’ll create a treatment plan that incorporates the most recent scientific advances and reflects your priorities. I see my role as that of teacher, coach and advisor — answering your questions, helping you think through the options and providing recommendations so that you can make sound decisions. I also think it’s important to discuss clinical trials when appropriate; depending on your diagnosis and health, trials are sometimes the best option for treatment, and they are also a vital part of advancing cancer care for future generations.

Provider background

Specialty: Medical Oncology

Plasma cell disorders

I am a hematologist-oncologist who specializes in treating multiple myeloma and other plasma cell disorders. In addition to caring for patients at SCCA, I am an active clinical researcher, helping to conduct studies investigating therapies for multiple myeloma, AL amyloidosis and Waldenstrom’s macroglobulinemia. I am also a member of the Fred Hutchinson Cancer Research Center’s Scientific Review Committee, where I examine the feasibility and merit of research protocols. Teaching has always been an important part of my career; as a UW assistant professor of medicine in the Division of Oncology, I enjoy teaching medical students and fellows about hematologic malignancies.

Amyloidosis

Following my residency, I worked at the Amyloidosis Center, an internationally recognized leader in the treatment and research of amyloidosis and related diseases. As part of a multidisciplinary patient care team, I also conducted clinical research in gastrointestinal amyloidosis and the impact of bone marrow amyloid deposits on stem cell transplantation.

Diseases treated

Education, experience and certifications
Undergraduate Degree
University of Washington
Medical Degree
University of Washington School of Medicine
Residency
Boston Medical Center, Internal Medicine
Fellowship
University of Washington/Fred Hutchinson Cancer Research Center, Hematology-Oncology; Boston University Amyloidosis Center, Amyloidosis
Board Certification
Internal Medicine; Hematology; Medical Oncology, American Board of Internal Medicine
Languages
English

Stories

At SCCA, multiple myeloma patient accesses hope—and a stem cell transplant
At SCCA, multiple myeloma patient accesses hope—and a stem cell transplant

In the summer of 2017, Lorrie Ann Sherman thought food poisoning was the reason she was throwing up and felt so weak she couldn’t even stand. At 42 years old, she was a health and fitness enthusiast who ran or did yoga daily, ate clean and favored cold press juices.

Research

Clinical trials

We make promising new treatments available to you through studies called clinical trials led by SCCA doctors. Many of these trials at SCCA have led to FDA-approved treatments and have improved standards of care globally. Together, you and your doctor can decide if a study is right for you.

Study ID:
NCT04771078
Expanded Access Protocol (EAP) for Subjects Receiving Idecabtagene Vicleucel That is Nonconforming for Commercial Release
Complete title
Expanded Access Protocol (EAP) for Subjects Receiving Idecabtagene Vicleucel that is Nonconforming for Commercial Release
Study ID:
NCT03374085
A Safety, PK and Efficacy Study of CC-92480 Monotherapy and in Combination With Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)
Complete title
A PHASE 1/2 MULTICENTER, OPEN-LABEL STUDY TO ASSESS THE SAFETY, PHARMACOKINETICS AND EFFICACY OF CC-92480 MONOTHERAPY AND IN COMBINATION WITH DEXAMETHASONE IN SUBJECTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA
Study ID:
NCT04883242
Isatuximab, Carfilzomib, Pomalidomide, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma
Complete title
Isatuximab, Carfilzomib, Pomalidomide, and Dexamethasone (Isa-KPd) for Patients with Relapsed/Refractory Multiple Myeloma

Publications

Many of our SCCA physicians conduct ongoing research to improve standards of patient care. Their work is evaluated by other physicians and selected for publication to the United States National Library of Medicine, the largest medical library in the world. See scientific papers this SCCA provider has written.

Press

SCCA providers are often asked to give their medical expertise for press and news publications. Read articles by or about this SCCA provider.

B-cell Maturation Antigen-Targeted Autologous CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma

SCCA’s Andrew J. Cowan spoke to Cancer Therapy Advisor about CART-cell therapy for relapsed, refractory multiple myeloma.

Gamma Secretase Inhibitor Improves Responses to BCMA CAR T Cells in Myeloma

SCCA’s Andrew Cowan, MD, provided commentary about a Phase 1 clinical trial evaluating the combination of a gamma-secretase inhibitor (GSI) therapy with BCMA CAR T cells to improve response in heavily pretreated patients that was presented at ASH 2019

Your care team

At SCCA, you receive care from a team of providers with extensive experience in your disease. Your team includes doctors, a team coordinator, a registered nurse, an advanced practice provider and others, based on your needs. You also have access to experts like nutritionists, social workers, acupuncturists, psychiatrists and more who specialize in supporting people with cancer or blood disorders.
Registered nurse (RN)
Registered nurse (RN)
Your nurse manages your care alongside your physician and assists with care procedures and treatments.
Team coordinator (TC)
Team coordinator (TC)
Your team coordinator works closely with you and your physician and serves as your scheduler.

Insurance

SCCA accepts most national private health insurance plans as well as Medicare. We also accept Medicaid for people from Washington, Alaska, Montana and Idaho. We are working to ensure that everyone, no matter what their financial situation, has access to the care they need.

For providers